How should family members with familial RUNX1 germline mutations be monitored?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jane Churpek, The University of Wisconsin, Madison, US. She talked about how people with familial RUNX1 germline mutations should be monitored?

Experts suggest monitoring the blood count every 6-12 months and potentially carrying out a baseline bone marrow biopsy. However many questions remain, including the need for molecular testing to monitor the acquisition of additional mutations, or whether the presence of a single additional mutation would impact on patients outcomes.